Dr. Katharina Sahm

Department of Neurology, University Medical Center Mannheim

European Center for Angioscience, Medical Faculty Mannheim

CCU Neuroimmunology and Brain Tumor Immunology,

German Cancer Research Center, Heidelberg

 

katharina.sahm(at)umm.de

Katharina Sahm attended the Medical Schools at the Universities Heidelberg and London. She obtained her MD at the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center and Department in Heidelberg under the supervision of Michael Platten. Currently, she is a Research Associate and Resident in Neurology at the Medical Faculty Mannheim and the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the DKFZ in Heidelberg.

Qualifications and Scientific Curriculum

2004-2011

2014

2012-2018

since 2018

Medical School, Universities of Heidelberg and London

MD, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center and Department of Neurooncology, University Hospital Heidelberg, Germany

Resident in Neurology, University Hospital Heidelberg and Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg

Research Associate and Resident in Neurology, Medical Faculty Mannheim, Heidelberg University and Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany

Selected publications

  1. Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M: K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology, 6:e1328340, 2017.

  2. Ochs K, Ott M, Rauschenbach KJ, Deumelandt K, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M: Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J Neurochem, doi:10.1111, 2015.

  3. Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M: Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol, 265:106-16, 2013.

  4. Breckwoldt MO, Bode J, Kurz FT, Hoffmann A, Ochs K, Ott M, Deumelandt K, Krüwel T, Schwarz D, Fischer M, Helluy X, Milford D, Kirschbaum K, Solecki G, Chiblak S, Abdollahi A, Winkler F, Wick W, Platten M, Heiland S, Bendszus M, Tews B: Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. Elife, 5:pii: e11712, 2016.

  5. Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, Pusch S, Opitz CA, Blaes J, von Deimling A, Wick W, Platten M: Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia, 63:78-90, 2015.

  6. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X, Anastasov N, Lehmann I, Höfer T, von Deimling A, Wick W, Platten M: Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget, 5:1038-51, 2014.

  7. Platten M, Ochs K, Lemke D, Opitz C, Wick W: Microenvironmental clues for glioma immunotherapy. Curr Neurol Neurosci Rep, 14:440, 2014.

  8. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M: The indoleamine-2,3- dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One, 6:e19823, 2011.

  9. Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K: Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Front Immunol, 5:673, 2015.

CRC1366

European Center for Angioscience

Medical Faculty Mannheim
Heidelberg University
Ludolf-Krehl-Straße 13-17
D-68167 Mannheim

Phone +49 621/383-71450